Excellence in Dermatology™
Excellence in Dermatologic Surgery™
Excellence in Medical Dermatology™
Excellence in Dermatopathology™

Return to program book search

Session Information

FRM F086 - Dermatologic Manifestations of New Oncology Drugs

Open admission to eligible categories, no tuition or ticket


Date: Sunday, March 23

CME Credits: 2.00

Location: Mile High Ballroom 3B

Time: 1:00 PM - 3:00 PM

Director: Mario E. Lacouture, MD, FAAD

  • Milan J. Anadkat, MD, FAAD
  • Jennifer N. Choi, MD, FAAD
  • Nicole LeBoeuf, MD, FAAD
  • Beth McLellan, MD, FAAD

Learning Objectives:
Following this course, the attendee should be able to:

  • Recognize clinical and histologic characteristics of dermatologic adverse events to new anticancer therapies.
  • Describe the mechanisms involved in dermatologic adverse events to therapies in cancer.
  • Discuss mechanistically-based interventions to improve quality of life and decrease dermatologic toxicities to anticancer therapies.

Systemic anticancer therapies (chemotherapy and targeted therapies), radiation, and surgeries have resulted in remarkable improvements in clinical outcomes in cancer, but the majority of patients will develop dermatologic adverse events, which lead to decreased quality of life and inconsistent antineoplastic therapy, both of which may affect survival. This session will provide a comprehensive understanding of dermatologic adverse events in cancer patients, so that dermatologists may play an integral role in the optimization of anticancer therapies and maintenance of quality of life.


Sunday, March 23
1:00 PMIntroduction to Supportive Oncodermatology / Dr. Lacouture
1:10 PMSkin Adverse Events Induced by Cyotoxic Chemotherapy (Alkylating, Antimetabolites, Topoisomerase inhibitors) / Dr. Anadkat
1:30 PMSkin Adverse Events Induced by Cyotoxic Chemotherapy (Antimicrotubule, ATRA, arsenic trioxide, bleomycin, asparaginase) / Dr. LeBoeuf
1:50 PMSkin Adverse Events Induced by Chemotherapy (Proteasome Inhibitors, Immunotherapies (IFN, ipilimumab, thalidomide, lenalidomide) / Dr. Choi
2:10 PMSkin Adverse Events Induced by EGFR, mTOR, and RAF inhibitors / Dr. Lacouture
2:30 PMHand Foot Syndrome, Hair, and Nail Changes / Dr. McLellan
2:50 PMQuestion and Answer Session / All faculty